Five-year antibody persistence and safety following a booster dose of combined haemophilus influenzae type b-neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine

Pediatric Infectious Disease Journal

Volumn 31, Issue 10, 2012, Pages 1074-1077

  Tejedor, Juan Carlos ^a   Merino, José Manuel ^b   Moro, Manuel ^c   Navarro, Maria Luisa ^d   Espín, José ^e   Omeñaca, Félix ^f   García Sicilia, José ^f   Moreno Pérez, David ^g   Ruiz Contreras, Jesús ^h   Centeno, Fernando ⁱ   Barrio, Francisco ^j   Cabanillas, Lucia ^k   Muro, Marta ^k   Esporrin, Carlos ^l   De Torres, Maria Jose ^m   Caubet, Magalie ⁿ   Boutriau, Dominique ⁿ   Miller, Jacqueline M ⁿ   Mesaros, Narcisa ⁿ  

^a HOSPITAL DE MÓSTOLES   (Spain)

^b HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL TORRECÁRDENAS   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^j Especialidad en Oftalmología Hospital Comarcal de la Axarquía Vélez Málaga Málaga   (Spain)

^k HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^l HOSPITAL SANTA CATERINA   (Spain)

^m GSK   (Belgium)

ⁿ GLAXOSMITHKLINE   (United States)

more..

Author keywords

antibody persistence; Haemophilus influenzae type b; Neisseria meningitidis serogroup C; safety; vaccination

Indexed keywords

ANTIBODY; HAEMOPHILUS INFLUENZAE VACCINE; MENINGOCOCCUS VACCINE; POLYRIBOSYLRIBITOL PHOSPHATE ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; CHILD; CONTROLLED STUDY; DRUG FATALITY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CHILD; CHILD, PRESCHOOL; COMPLEMENT SYSTEM PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MALE; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP C; TETANUS TOXOID; TIME FACTORS; VACCINES, CONJUGATE;

EID: 84866595092     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318269433a     Document Type: Article

References (19)

1. Borrow R, Andrews N, Findlow H, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus infuenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol. 2010;17:154-159.
2. Khatami A, Snape MD, John T, et al. Persistence of immunity following a booster dose of Haemophilus infuenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial. Pedi-atr Infect Dis J. 2011;30:197-202.
3. Díez-Domingo J, Cantarino M V, Torrentí JM, et al.; MenC Study Group. A randomized, multicenter, open-label clinical trial to assess the immuno-genicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr Infect Dis J. 2010;29:148-152.
4. Diez-Domingo J, Planelles-Cantarino M V, Baldo-Torrenti JM, et al. Antibody persistence 12 months after a booster dose of meningococcal-C conjugated vaccine in the second year of life. Pediatr Infect Dis J. 2010;29:768-770.
5. Tejedor JC, Moro M, Ruiz-Contreras J, et al. for the Spanish DTPa-HBV-IPV-097 Study Group. Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus infuenzae Type b and Neisseria meningitidis Serogroup C-tetanus toxoid conjugate vaccine coadministered with a Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated poliovi-rus vaccine at 2, 4 and 6 months. Pediatr Infect Dis J. 2007;26:1-7.
6. Tejedor JC, Moro M, Merino JM, et al. Spanish 102547 Study Group. Immu-nogenicity and reactogenicity of a booster dose of a novel combined Haemo-philus infuenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age. Pediatr Infect Dis J. 2008;27:579-588.
7. EU-IBIS Network. Invasive Neisseria meningitidis in Europe 2006. London, United Kingdom: Health Protection Agency; 2006.
8. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using effcacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10:780-786.
9. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine. 2005;23:2222-2227.
10. Käyhty H, Peltola H, Karanko V, et al. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus infuenzae type b. J Infect Dis. 1983;147:1100.
11. Anderson P. The protective level of serum antibodies to the capsular polysac-charide of Haemophilus infuenzae type b. J Infect Dis. 1984;149:1034-1035.
12. Clopper CJ, Pearson ES. The use of confdence or fducial limits illustrated in the case of binomial. Biometrika. 1934;26:404-413.
13. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17:873-890.
14. Fusco PC, Farley EK, Huang CH, et al. Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation. Clin Vaccine Immunol. 2007;14:577-584.
15. Borrow R, Findlow J. Prevention of meningococcal serogroup C disease by NeisVac-C. Expert Rev Vaccines. 2009;8:265-279.
16. Miller JM, Mesaros N, Van Der Wielen M, et al. Conjugate Meningococ-cal Vaccines Development: GSK Biologicals Experience. Adv Prev Med. 2011;2011:846756.
17. Schmitt HJ, Maechler G, Habermehl P, et al. Immunogenicity, reactogenic-ity, and immune memory after primary vaccination with a novel Haemophi-lus infuenzae-Neisseria meningitidis serogroup C conjugate vaccine. Clin Vaccine Immunol. 2007;14:426-434.
18. Southern J, Borrow R, Andrews N, et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol. 2009;16:194-199.
19. Kitchin NR, Southern J, Morris R, et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus infuenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch Dis Child. 2007;92:11-16.